Baycrest Academy of Health Sciences and Geriatric Research
Toronto, Ontario, M6A 2E1, Canada
Location status: Recruiting
NCT Number: NCT07291687
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigation will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease.
Interested in participating?
Request InfoAll sexes
Interventional
Not applicable
Toronto, Ontario, M6A 2E1, Canada
Location status: Recruiting
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigators will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease. The rationale for including people living with these conditions is the overlap in motor and cortical network dysfunction observed across these disorders. All three conditions involve impairment of motor initiation, gait, coordination, and executive motor control due to degeneration in frontal-subcortical pathways. This extension will also allow for comparison of stimulation responsiveness across related diagnostic groups and provide insight into disease-specific factors influencing motor recovery potential.
Previous tDCS studies have found significant results with sample sizes between 10-20 participants for a two-round study comparing training sessions with real tDCS versus sessions done without tDCS. However, the investigators plan to recruit 30 participants living with each condition as this will allow us to examine results per group, but also how the individual groups compare.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Crossover design will enable us to use each participant as their own control.
Participants will be exposed to the brain stimulation protocol while undergoing certain motor task during the training sessions.
Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.
Within each round, scores from the final week and final session of real tDCS stimulation will be compared to performance during the first week and final sham tDCS session to check for significant improvement. Our primary outcome measures will be those found for gait; for example, a faster walking time subsequent to tDCS stimulation compared to the placebo baseline. Participants will also return two weeks later for a post-stimulation evaluation to check if improvement was maintained. To check if the arrangement of electrodes impacts the effect, times from the final tDCS session of each round will be compared.
Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.
Articulation will be assessed using a clinician-administered repetition task involving single words and short sentences. Speech production quality will be rated by the clinician using a standardized 5-point articulation quality scale (1 = severely distorted, 5 = normal/near-normal production). The reported value will be the rating score.
Time frame: Measures collected at three points each round: baseline in week 1, post-treatment at the final stimulation session, and follow-up two weeks after the final session.
Eye-gaze performance will be evaluated using a bedside oculomotor task. Participants are asked to follow a moving pencil with their eyes while keeping their head still. A clinician will rate eye-gaze control on a standardized 3-point scale (0 = unable, 1 = inconsistent, 2 = consistent and accurate). The reported value will be the rating score.
Contact information is provided by the study sponsor or research team.
Alice Zhang, B.Sc
CONTACT
(416) 785-2500 ext. 2522
Tyler Roncero, Ph.D
CONTACT
T (416) 785-2500 ext. ext. 2522
Baycrest
Other
Transcranial Direct Current Stimulation as a Treatment for Motor Function in Participants Living With Progressive Supranuclear Palsy, Corticalbasal Syndrome Degeneration, or Parkinson's Disease
Acronym: PSP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03174938
ALS (Amyotrophic Lateral Sclerosis), Alzheimer Disease
Ängelholm, Sweden
View Trial DetailsNCT06529744
Alzheimer Disease, Aphasia
North York, Ontario, Canada
View Trial DetailsNCT06203106
ALS, Adnexal Diseases
New York, United States
View Trial DetailsNCT05222386
Autonomic Nervous System Diseases, Basal Ganglia Diseases
Rochester, New York, United States
View Trial Details